We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
高シグナルの見出しのみ — マクロイベント、決算、M&A、規制。リスト記事とアナリストのクリックベイトはデフォルトでフィルタ。1時間ごとに更新。
Regenxbio Inc (NASDAQ:RGNX) is one of the best gene therapy stocks to buy in 2026. On May 14, Regenxbio reported its Q1 2026 financial results and provided operational updates. The company exited the quarter with $150.5 million in cash. The management expects the cash balance to be enough to fund operations into early 2027. Regenxbio […]
One is a well-known pharmaceutical company; the other is the king of the medical device segment.
Cortrophin Gel is reshaping ANI Pharmaceuticals into a specialty-driven growth story, with 2026 revenue guidance signaling another major leap.
AbbVie (ABBV) is back in focus after presenting fresh real world and long term data for its key immunology drugs SKYRIZI and RINVOQ at the 2026 Digestive Disease Week meeting. See our latest analysis for AbbVie. Those fresh immunology data and a string of recent conference appearances come as AbbVie’s share price has eased this year, with a year to date share price return of down 9.35%, even though the 1 year total shareholder return is 14.17% and the 5 year total shareholder return is...
AbbVie Inc. (NYSE:ABBV) is one of the best healthcare stocks to buy for the long term. AbbVie Inc. (NYSE:ABBV) received a rating update from Evercore ISI on May 4, with the firm lifting the price target on the stock to $236 from $232 while maintaining an Outperform rating on the shares. The company also announced […]
How does a rising 3.4% dividend and a growing portfolio of drugs sound?
It's not the news that AbbVie needed, given the challenging year it is having.
IRWD beats Q1 earnings and revenue estimates with Linzess sales surging on strong demand, but shares slide despite better-than-expected results.
They have combined for 118 years of consecutive dividend increases.
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.